ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · IEX Real-Time Price · USD
10.54
+0.09 (0.91%)
At close: Jul 19, 2024, 4:00 PM
11.00
+0.46 (4.36%)
Pre-market: Jul 22, 2024, 7:01 AM EDT
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ARS Pharmaceuticals stock have an average target of 18.5, with a low estimate of 18 and a high estimate of 19. The average target predicts an increase of 75.52% from the current stock price of 10.54.
Analyst Consensus: Buy
* Price targets were last updated on Mar 11, 2024.
Analyst Ratings
The average analyst rating for SPRY stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Wedbush | Wedbush | Buy Reiterates $19 | Buy | Reiterates | $19 | +80.27% | Mar 11, 2024 |
Leerink Partners | Leerink Partners | Hold → Buy Upgrades $6 → $18 | Hold → Buy | Upgrades | $6 → $18 | +70.78% | Mar 5, 2024 |
Wedbush | Wedbush | Buy Maintains $5 → $13 | Buy | Maintains | $5 → $13 | +23.34% | Nov 13, 2023 |
Wedbush | Wedbush | Buy Maintains $15 → $5 | Buy | Maintains | $15 → $5 | -52.56% | Sep 21, 2023 |
William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 20, 2023 |
Financial Forecast
Revenue This Year
6.47M
from 30.00K
Increased by 21,456.67%
Revenue Next Year
60.87M
from 6.47M
Increased by 841.30%
EPS This Year
-0.66
from -0.57
EPS Next Year
-0.64
from -0.66
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 8.4M | 67.2M | 233.8M | 395.9M | 644.1M |
Avg | 6.5M | 60.9M | 198.9M | 347.8M | 570.1M |
Low | 4.6M | 54.3M | 164.0M | 298.8M | 494.4M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 27,900.0% | 939.1% | 284.1% | 99.1% | 85.2% |
Avg | 21,456.7% | 841.3% | 226.7% | 74.9% | 63.9% |
Low | 15,186.7% | 738.9% | 169.3% | 50.2% | 42.2% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | -0.64 | -0.63 | 0.65 | 0.56 |
Avg | -0.66 | -0.64 | 0.32 | 0.54 |
Low | -0.68 | -0.64 | - | 0.52 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | - | - | - | 76.0% |
Avg | - | - | - | 71.0% |
Low | - | - | - | 64.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.